癌症中的核结相关蛋白-1-真正的价值
Marlena Janiczek-Polewska1,2, Tomasz Kolenda3, Paulina Poter4
1Department of Clinical Oncology, Greater Poland Cancer Center, 61-866 Poznan, Poland.
International journal of molecular sciences
|January 8, 2025
概括
核聚关联蛋白1 (NACC1) 参与了许多癌症,影响了病变发生和免疫反应. 虽然不是诊断生物标志物,但NACC1显示出作为改善癌症治疗有效性的治疗点的潜力.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 癌症研究 癌症研究
背景情况:
- 恶性瘤是全球主要的死亡原因,存在重大诊断和治疗挑战.
- 了解癌症的多样性致病源是开发有效治疗方法的关键.
- 核聚关联蛋白1 (NACC1),一种转录性核心调节剂,与促进瘤发生有关.
研究的目的:
- 使用癌症基因组图谱 (TCGA) 数据分析各种癌症中的NACC1表达.
- 调查NACC1表达和临床病理学参数之间的相关性.
- 评估NACC1作为癌症诊断生物标志物和治疗点的潜力.
主要方法:
- 利用了通过阿拉巴马大学伯明翰癌症 (UALCAN) 数据库访问的癌症基因组图集 (TCGA) 数据,用于NACC1表达分析.
- 相互连接的NACCC1表达数据与临床病理参数.
- 使用GraphPad Prism和Statistica进行统计分析.
主要成果:
- 发现NACC1在几乎所有分析的癌症类型中都表达.
- 与各种临床病理学参数相关的NACC1表达水平.
- 这项研究表明,NACCC1参与了癌症的发病,侵袭和免疫反应.
结论:
- NACC1在恶性瘤中广泛表达,并在癌症的发展和进展中发挥作用.
- 由于缺乏特异性和表达差异,NACC1不是一个合适的诊断生物标志物.
- 针对NACC1进行治疗可能会提高癌症治疗的疗效.
相关概念视频
Abnormal Proliferation
4.4K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.4K
mTOR Signaling and Cancer Progression
3.7K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.7K
The Nucleolus
8.7K
The nucleolus is the most prominent substructure of the nucleus. When it was first discovered, it was considered to be an isolated organelle that forms fibrils and granules. In 1931, the relationship between the nucleolus and chromosomes was first described by Heitz. He observed that the appearance and size of nucleolus varies depending on the stage of the cell cycle. He also noticed constricted regions on different chromosomes clustered together at definite cell cycle stages. These regions,...
8.7K
lncRNA - Long Non-coding RNAs
8.5K
In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
8.5K
The Intrinsic Apoptotic Pathway
6.4K
Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
6.4K
Cancer Cell Migration through Invadopodia
2.3K
Invadosome is a broad category of cell surface structures with proteolytic activity that degrades the extracellular matrix (ECM). Invadosomes are present in normal cell types, including macrophages, endothelial cells, and neurons, as well as tumor cells. Although the macrophage podosomes and tumor cell invadopodia are classified as invadosomes, they have different structures, molecular pathways, and functions. Podosomes are short structures that last for a few minutes. However,...
2.3K


